Full Text View
Tabular View
No Study Results Posted
Related Studies
Vaccine Therapy Plus Interleukin-2 in Treating Patients With Stage III or Stage IV Melanoma
The recruitment status of this study is unknown because the information has not been verified recently.
Verified April 2002 by National Cancer Institute (NCI).
Recruitment status was  Active, not recruiting
Study NCT00003222   Information provided by National Cancer Institute (NCI)

First Received on November 1, 1999.   Last Updated on February 6, 2009   History of Changes
Related Studies can be found by searching for the Conditions, Interventions, and Sponsors found in this study:
Conditions listed in this trial
Melanoma (Skin)
Additional conditions recognized in this trial
Melanoma
More general conditions related to this trial
Neoplasms
Neoplasms by Histologic Type
Neoplasms, Germ Cell and Embryonal
Neoplasms, Nerve Tissue
Neuroectodermal Tumors
Neuroendocrine Tumors
Nevi and Melanomas
Interventions listed in this trial
aldesleukin
gp100 antigen
incomplete Freund's adjuvant
sargramostim
tetanus peptide melanoma vaccine
tyrosinase peptide
Additional drug interventions recognized in this trial
Adjuvants, Immunologic
Freund's Adjuvant
More general drug interventions related to this trial
Anti-HIV Agents
Anti-Infective Agents
Anti-Retroviral Agents
Antineoplastic Agents
Antiviral Agents
Immunologic Factors
Pharmacologic Actions
Physiological Effects of Drugs
Therapeutic Uses
Sponsors listed in this trial
University of Virginia
National Cancer Institute (NCI)


Contact Help Desk
Lister Hill National Center for Biomedical Communications,  U.S. National Library of Medicine,
U.S. National Institutes of Health,  U.S. Department of Health & Human Services,
USA.gov,  Copyright,  Privacy,  Accessibility,  Freedom of Information Act

U.S. National Institutes of Health U.S. National Library of Medicine U.S. Department of Health & Human Services